Bridge City Capital LLC reduced its stake in Natus Medical Incorporated (NASDAQ:NTUS – Get Rating) by 0.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 103,165 shares of the company’s stock after selling 482 shares during the quarter. Natus Medical makes up 1.3% of Bridge City Capital LLC’s investment portfolio, making the stock its 29th largest holding. Bridge City Capital LLC owned 0.30% of Natus Medical worth $2,711,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank N A MO purchased a new stake in Natus Medical in the 4th quarter valued at $29,000. Captrust Financial Advisors raised its position in Natus Medical by 138.3% in the 1st quarter. Captrust Financial Advisors now owns 1,823 shares of the company’s stock valued at $48,000 after buying an additional 1,058 shares during the last quarter. Pinebridge Investments L.P. purchased a new stake in Natus Medical in the 4th quarter valued at $50,000. Prospera Financial Services Inc purchased a new stake in Natus Medical in the 1st quarter valued at $60,000. Finally, SG Americas Securities LLC purchased a new stake in Natus Medical in the 1st quarter valued at $106,000. 92.35% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on Natus Medical in a research report on Tuesday. They set a “buy” rating for the company.
Natus Medical Price Performance
Natus Medical Company Profile
Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.
- Get a free copy of the StockNews.com research report on Natus Medical (NTUS)
- Is Five Below Trying to Punch Too High?
- These 3 Reports Will Tell Us Much About the Current Economy
- This Is What To Expect From The S&P 500 Now
- The Two Things You Need To Know About Oracle’s FQ1 Report
- Three Value Stocks For A Volatile Market
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.